Konior R, Brzostek J, Poellabauer E M, Jiang Q, Harper L, Erber W
John Paul II Hospital, Krakow, Poland.
Debica, Poland.
Vaccine. 2017 Jun 16;35(28):3607-3613. doi: 10.1016/j.vaccine.2017.03.059. Epub 2017 May 22.
Tick-borne encephalitis (TBE) is a viral disease that can have a severe acute clinical course and considerable long-term morbidity. As there is no causal treatment currently available for TBE, vaccination is the only way to combat the disease in endemic areas. The studies presented here were conducted to obtain prospective long-term TBE serum antibody persistence data of subjects up to 10years after the first booster with FSME-IMMUN. This report presents the results of 2 follow-up studies in the same study population of 315 healthy adults. Blood was drawn to assess the seropersistence of TBE virus antibodies yearly, from 2-5 and 7-10years after the first booster vaccination with FSME-IMMUN administered during a previous study. The timing of the second booster vaccination was dependent on the level of serum TBE antibodies observed during yearly follow-up serology observations. The current follow up showed that adult recipients were 84.9% seropositive 10years after a 3 dose primary series and the first booster vaccination of FSME-IMMUN. Seropositivity rates were even higher (88.6%) in subjects below 50years of age. ClinicalTrials.gov Identifier: NCT00503529. ClinicalTrials.gov Identifier: NCT01582698.
蜱传脑炎（TBE）是一种病毒性疾病，可呈现严重的急性临床病程并伴有相当程度的长期发病率。由于目前尚无针对蜱传脑炎的特效治疗方法，接种疫苗是在流行地区对抗该疾病的唯一途径。此处开展的研究旨在获取受试者在首次接种FSME-IMMUN加强针后长达10年的前瞻性长期蜱传脑炎血清抗体持久性数据。本报告呈现了对315名健康成年人这一相同研究群体进行的2项随访研究结果。在前一项研究中，在首次接种FSME-IMMUN加强针后的第2至5年以及第7至10年，每年采集血液以评估蜱传脑炎病毒抗体的血清持久性。第二次加强针接种的时间取决于每年随访血清学观察中所观察到的血清蜱传脑炎抗体水平。当前的随访显示，在完成3剂基础免疫系列和首次接种FSME-IMMUN加强针10年后，成年接种者的血清阳性率为84.9%。50岁以下受试者的血清阳性率更高（88.6%）。临床试验注册号：NCT00503529。临床试验注册号：NCT01582698。
